In medicine, antineoplastic agents are "substances that inhibit or prevent the proliferation of neoplasms", otherwise known as cancers.[1] Generally, antineoplastic agents are for treating malignant neoplasms such as cancers and sarcomas.
Classification[edit]
This classification is based on World Health Organization's Collaborating Centre for Drug Statistics Methodology.[2]
Alkylating agents[edit]
ATC/DDD group L01A. Alkylating antineoplastic agents are a "class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood."[3]
Nitrogen mustard analogues[edit]
ATC/DDD group L01AA. Examples include cyclophosphamide, chlorambucil, melphalan.
Alkyl sulfonates[edit]
ATC/DDD group L01AB.
Ethylene imines[edit]
ATC/DDD group L01AC.
Nitrosoureas[edit]
ATC/DDD group L01AD.
Epoxides[edit]
ATC/DDD group L01AG.
Other alkylating agents[edit]
ATC/DDD group L01AX.
Antimetabolites[edit]
ATC/DDD group L01B. Antineoplastic antimetabolites are "antimetabolites that are useful in cancer chemotherapy."[4]
Folic acid analogues[edit]
ATC/DDD group L01BA. Examples include:
Purine analogues[edit]
ATC/DDD group L01BB. Examples include:
Pyrimidine analogues[edit]
ATC/DDD group L01BC. Examples include:
Plant alkaloids and other natural products[edit]
ATC/DDD group L01C.
Vinca alkaloids and analogues[edit]
ATC/DDD group L01CA.
Podophyllotoxin derivatives[edit]
ATC/DDD group L01CB. Examples include etoposide.
Colchicine derivatives[edit]
ATC/DDD group L01CC.
Taxanes[edit]
ATC/DDD group L01CD.
Other plant alkaloids and natural products[edit]
ATC/DDD group L01CX.
Cytotoxic antibiotics and related substances[edit]
ATC/DDD group L01D.
Actinomycines[edit]
ATC/DDD group L01DA.
Anthracyclines and related substances[edit]
ATC/DDD group L01DB.
Other cytotoxic antibiotics[edit]
ATC/DDD group L01DC.
Other antineoplastic agents[edit]
ATC/DDD group L01X.
Platinum compounds[edit]
ATC/DDD group L01XA examples include cisplatin, carboplatin, oxaliplatin, and satraplatin.
Methylhydrazines[edit]
ATC/DDD group L01XB.
Monoclonal antibodies[edit]
ATC/DDD group L01XC. Examples include:
- Anti-EpCAM
- Anti-ErbB1
- Anti-ErbB2
- Anti-CD3 and anti-EpCAM
- Catumaxomab. Is a monoclonal antibody against CD3 (Entrez protein)and EpCAM (Entrez protein). "Extracorporeal PBMNC coating with catumaxomab may be an option to control intravascular cytokine release induced by therapeutic antibodies".[12]
- Anti-MS4A1 (CD20 antigen)
- Anti-SIGLEC3 (CD33)
- Anti-CD52
- Alemtuzumab is a "a therapeutic antibody directed against the CDw52 antigen (Entrez protein) expressed by the lymphocytes and has proven lytic abilities both in vitro and in vivo; has been sequenced".[15]
- Anti-VEGF
- Bevacizumab is an "anti-VEGF (Entrez protein) monoclonal antibody consisting of humanized murine antibody with antigen-binding, complementary-determining regions from murine VEGF".[16]
Sensitizers used in photodynamic/radiation therapy[edit]
ATC/DDD group L01XD.
Protein kinase inhibitors[edit]
ATC/DDD group L01XE. Examples include imatinib, gefitinib, erlotinib, sunitinib, sorafenib, dasatinib, lapatinib, nilotinib, and temsirolimus.
Other antineoplastic agents[edit]
ATC/DDD group L01XX. Examples include hydroxycarbamide (hydroxyurea), tretinoin, and celecoxib.
Dosage may be by the area under the curve (AUC), expressed at mg/mL * min.
References[edit]
- ↑ Anonymous (2024), Antineoplastic agent (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous. WHO Collaborating Centre for Drug Statistics Methodology. World Health Organization. Retrieved on 2009-02-04.
- ↑ Anonymous (2024), Antineoplastic Agents, Alkylating (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Antineoplastic Agents, Alkylating (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Methotrexate (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Mercaptopurine (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), cytarabine (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), edrecolomab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A et al. (2009). "Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.". N Engl J Med 360 (14): 1408-17. DOI:10.1056/NEJMoa0805019. PMID 19339720. Research Blogging.
- ↑ Anonymous (2024), Panitumumab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Trastuzumab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Catumaxomab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Rituximab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Gemtuzumab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Alemtuzumab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Bevacizumab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.